Alivus Life Sciences Ltd.

The September 2021 quarter revenue stood at Rs. 5617.61 millions, up 7.86% as compared to Rs. 5208.05 millions during the corresponding quarter last year.Net profit for the quarter ended September 2021 increased significantly by 58.96% to Rs. 1152.01 millions from Rs. 724.70 millions.Operating profit for the quarter ended September 2021 rose to 1694.26 millions as compared to 1269.30 millions of corresponding quarter ended September 2020.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202109	202009	% Var	202109	202009	% Var	202109	202009	% Var
Sales	5617.61	5208.05	7.86	5617.61	5208.05	7.86	5617.61	5208.05	7.86
Other Income	20.89	0.12	17308.33	20.89	0.12	17308.33	20.89	0.12	17308.33
PBIDT	1694.26	1269.30	33.48	1694.26	1269.30	33.48	1694.26	1269.30	33.48
Interest	72.26	219.04	-67.01	72.26	219.04	-67.01	72.26	219.04	-67.01
PBDT	1622.00	1050.26	54.44	1622.00	1050.26	54.44	1622.00	1050.26	54.44
Depreciation	96.65	83.49	15.76	96.65	83.49	15.76	96.65	83.49	15.76
PBT	1525.35	966.77	57.78	1525.35	966.77	57.78	1525.35	966.77	57.78
TAX	373.34	242.07	54.23	373.34	242.07	54.23	373.34	242.07	54.23
Deferred Tax	7.91	12.64	-37.42	7.91	12.64	-37.42	7.91	12.64	-37.42
PAT	1152.01	724.70	58.96	1152.01	724.70	58.96	1152.01	724.70	58.96
Equity	245.05	19.60	1150.26	245.05	19.60	1150.26	245.05	19.60	1150.26
PBIDTM(%)	30.16	24.37	23.75	30.16	24.37	23.75	30.16	24.37	23.75